Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Clamp, AR"'
Autor:
McNeish, I, Morgan, RD, Cook, AD, James, EC, Lord, R, Dark, G, Glasspool, RM, Krell, J, Parkinson, C, Poole, CJ, Hall, M, Gallardo-Rincón, D, Lockley, M, Essapen, S, Summers, J, Anand, A, Zachariah, A, Williams, S, Jones, R, Scatchard, K, Walther, A, Kim, J-W, Sundar, S, Jayson, GC, Ledermann, JA, Clamp, AR
BackgroundPlatinum-based neoadjuvant chemotherapy (NACT) followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced stage epithelial ovarian cancer. Although this therapeutic approach has been valida
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1032::9636d15c7a38b268fbe7c56d2b27da23
http://hdl.handle.net/10044/1/83730
http://hdl.handle.net/10044/1/83730
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rosa DD, Clamp AR, Collinson F, Jayson GC, Rosa, Daniela D, Clamp, Andrew R, Collinson, Fiona, Jayson, Gordon C
Publikováno v:
Current Opinion in Oncology; 2007 Sep, Vol. 19 Issue 5, p497-505, 9p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Clamp, AR
Background Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a significant improvement in progression-free and overall survival with dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1532038b93579bbacd397aa12d1bb32d
https://www.repository.cam.ac.uk/handle/1810/303131
https://www.repository.cam.ac.uk/handle/1810/303131
Autor:
Morgan RD; The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Manchester, United Kingdom. Electronic address: robert.morgan7@nhs.net., Burghel GJ; Manchester Centre for Genomic Medicine, North West Genomic Laboratory Hub, Manchester, United Kingdom; Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health, School of Biological Sciences, University of Manchester, Manchester, United Kingdom., Flaum N; The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Manchester, United Kingdom., Schlecht H; Manchester Centre for Genomic Medicine, North West Genomic Laboratory Hub, Manchester, United Kingdom., Clamp AR; The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Manchester, United Kingdom., Hasan J; The Christie NHS Foundation Trust, Manchester, United Kingdom., Mitchell C; The Christie NHS Foundation Trust, Manchester, United Kingdom., Salih Z; The Christie NHS Foundation Trust, Manchester, United Kingdom., Moon S; University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom., Hogg M; Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom., Lord R; Clatterbridge Cancer Centre, Liverpool, United Kingdom., Forde C; Manchester Centre for Genomic Medicine, North West Genomic Laboratory Hub, Manchester, United Kingdom; Manchester University NHS Foundation Trust, Manchester, United Kingdom., Lalloo F; Manchester Centre for Genomic Medicine, North West Genomic Laboratory Hub, Manchester, United Kingdom; Manchester University NHS Foundation Trust, Manchester, United Kingdom., Woodward ER; Manchester Centre for Genomic Medicine, North West Genomic Laboratory Hub, Manchester, United Kingdom; Manchester University NHS Foundation Trust, Manchester, United Kingdom., Crosbie EJ; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Manchester, United Kingdom; Manchester University NHS Foundation Trust, Manchester, United Kingdom., Taylor SS; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Manchester, United Kingdom., Jayson GC; The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Manchester, United Kingdom., Evans DGR; Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health, School of Biological Sciences, University of Manchester, Manchester, United Kingdom; Manchester University NHS Foundation Trust, Manchester, United Kingdom. Electronic address: gareth.d.evans@manchester.ac.uk.
Publikováno v:
Genetics in medicine : official journal of the American College of Medical Genetics [Genet Med] 2024 Jul 31; Vol. 26 (10), pp. 101230. Date of Electronic Publication: 2024 Jul 31.